Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free halo Stock Alerts $39.12 +0.15 (+0.38%) (As of 04/24/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 7After Market ClosesConfirmedActual EPS (Feb. 20) $0.75 Missed By -$0.02 Consensus EPS (Feb. 20) $0.77 Get Halozyme Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for HALO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueHALO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.HALO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Halozyme Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243$0.58$0.77$0.69 Q2 20243$0.64$0.92$0.77 Q3 20243$0.85$0.98$0.93 Q4 20243$0.94$1.25$1.05 FY 202412$3.01$3.92$3.43 Q1 20251$0.85$0.85$0.85 Q2 20251$0.90$0.90$0.90 Q3 20251$1.01$1.01$1.01 Q4 20251$1.15$1.15$1.15 FY 20254$3.91$3.91$3.91 Q1 20261$1.21$1.21$1.21 HALO Earnings Date and InformationHalozyme Therapeutics last issued its earnings results on February 20th, 2024. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by $0.02. The firm earned $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics has generated $2.11 earnings per share over the last year ($2.11 diluted earnings per share) and currently has a price-to-earnings ratio of 18.5. Earnings for Halozyme Therapeutics are expected to grow by 23.77% in the coming year, from $3.45 to $4.27 per share. Halozyme Therapeutics has confirmed that its next quarterly earnings report will be published on Tuesday, May 7th, 2024. Halozyme Therapeutics will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call.. Read More Halozyme Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/7/2024Confirmed)------- 2/20/2024Q4 2023$0.77$0.75($0.02)$0.85$235.25 million$230.04 million11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47 million$216.03 million8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91 million$221.04 million5/9/2023Q1 2023$0.44$0.43($0.01)$0.57$174.20 million$162.14 million2/21/2023Q4 2022$0.43$0.44+$0.01$0.46$186.07 million$181.50 million11/8/2022Q3 2022$0.49$0.70+$0.21$0.96$187.87 million$208.98 million Get the Latest News and Ratings for HALO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2022Q2 2022$0.47$0.50+$0.03$0.84$156.00 million$152.37 million 5/10/2022Q1 2022$0.45$0.43($0.02)$0.43$128.25 million$117.30 million 2/22/2022Q4 2021$0.35$0.39+$0.04$0.32$97.10 million$102.00 million11/2/2021Q3 2021$0.42$1.48+$1.06($0.44)$101.94 million$115.83 million 8/9/2021Q2 2021$0.43$0.62+$0.19$0.64$104.08 million$136.50 million 5/10/2021Q1 2021$0.32$0.37+$0.05$0.49$84.88 million$89.02 million Halozyme Therapeutics Earnings - Frequently Asked Questions When is Halozyme Therapeutics's earnings date? Halozyme Therapeutics has confirmed that its next quarterly earnings data will be published on Tuesday, May 7th, 2024. Learn more on HALO's earnings history. Did Halozyme Therapeutics beat their earnings estimates last quarter? In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) missed the analysts' consensus estimate of $0.77 by $0.02 with a reported earnings per share (EPS) of $0.75. Learn more on analysts' earnings estimate vs. HALO's actual earnings. How much revenue does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $829.25 million. How much profit does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $2.11 earnings per share over the last four quarters. What is Halozyme Therapeutics's price-to-earnings ratio? Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 18.54 and a forward price-to-earnings ratio of 11.34. The price/earnings-to-growth ratio is 0.45. What is Halozyme Therapeutics's EPS forecast for next year? Halozyme Therapeutics's earnings are expected to grow from $3.45 per share to $4.27 per share in the next year, which is a 23.77% increase. More Earnings Resources from MarketBeat Related Companies: EXEL Earnings Date RLAY Earnings Date ALLO Earnings Date RGEN Earnings Date NVAX Earnings Date FATE Earnings Date ADPT Earnings Date KOD Earnings Date NBIX Earnings Date KRYS Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:HALO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
